Everest Organics is an API manufacturer based in India. It holds 16 active US drug master files across a filed portfolio of 5 molecules. Its GMP standing is certified by EMA and US FDA. Its most recent recorded inspection, by US FDA, closed on 1 March 2024 as NAI. Customs aggregates show $3.4M of exports covering 89 molecules to 21 destinations in 2025.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| Sangareddy, India | 3008616840 |
| Sadasivpet, India | Not on file |
| Molecule | Regulators | Docs |
|---|---|---|
| Omeprazole | SFDA (Saudi Arabia), US FDA | 9 |
| Bempedoic Acid | US FDA | 2 |
| Esomeprazole | US FDA | 2 |
| Pantoprazole | US FDA | 2 |
| Vonoprazan | US FDA | 2 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| MINSA (CR) | 2 | None |
| EMA | None | 1 |
| US FDA | None | 1 |
| Year | Revenue | Exports | Destinations |
|---|---|---|---|
| 2026 YTD | Not reported | $331K | 9 |
| 2025 | Not reported | $3.4M | 21 |
| 2024 | Not reported | $3.3M | 21 |
| 2023 | Not reported | $5.2M | 22 |
Export figures are customs aggregates. We do not publish the identity of any buyer.
Choose your molecules and target markets. Everest Organics comes back tiered against every other supplier able to file there.
Start for free